联环药业：目前有6个创新药 智通财经6月10日电，联环药业(600513.SH)发布投资者关系活动记录表，公司创新药目前主要布局心血 管、泌尿系统、抗肿瘤药、呼吸系统等方面，目前有6个创新药，有1个进入III期，2个正在进行I期临床 试验，3个处于临床前相关研究。公司在研产品LH-2103目前临床进行IIT（研究者发起的临床研究）和 DDI（药物相互作用）研究,LH-1801目前处于临床3期阶段，已完成临床3期单药和联合用药患者入组， 将持续开展单药和联合用药患者给药与随访工作。 ...

金十数据6月10日讯，联环药业6月10日晚间公告，近日，公司收到天津市市场监督管理委员会下发的 《行政处罚决定书》。天津市市场监督管理委员会认为，公司与具有竞争关系的经营者，以垄断协议形 式变更、固定地塞米松磷酸钠原料药价格，排除、限制了地塞米松磷酸钠原料药销售领域的竞争，违反 了《反垄断法》的相关规定，属于达成并实施"固定或者变更商品价格"垄断协议的行为，应当依法追究 法律责任。天津市市场监督管理委员会决定责令公司停止违法行为，并对公司处以罚没款合计6103.82 万元。 此次罚没金额占公司最近一个会计年度净利润的72.53%，将相应减少公司2025年度净利润 6103.82万元。 联环药业：收到行政处罚决定书 罚没款合计6103.82万元 ...

宁波美诺华药业股份有限公司 章 程 （2025 年 6 月修订） 宁波美诺华药业股份有限公司章程 宁波美诺华药业股份有限公司章程 宁波美诺华药业股份有限公司章程 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证 券法》（以下简称《证券法》）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下 简称"公司"）。 诉公司，公司可以起诉股东、董事、监事、总经理和其他高级管理人员。 第十一条 本章程所称其他高级管理人员是指公司的副总经理、董事会秘书、 财务负责人或公司董事会确定为高级管理人员的其他人员。 公司系由 2004 年 2 月 19 日成立的宁波亿贸进出口有限公司整体变更设立的 股份有限公司，并于 2012 年 2 月 14 日经宁波市工商行政管理局依法核准登记注 册，取得注册号为 330215000002952 的《企业法人营业执照》。 第三条 公司于 2017 年 3 月 10 日经中国证券监督管理委员会批准，首次向 社会公众发行人民币普通股 3,000 万 ...

证券代码：603538 证券简称：美诺华 公告编号：2025-073 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 开第五届董事会第十五次会议、第五届监事会第十五次会议，分别审议通过了《关 于调整公司 2021 年股票期权与限制性股票激励计划股票期权行权价格的议案》， 具体情况如下： 一、公司 2021 年股票期权与限制性股票激励计划基本情况 （一）本次激励计划已履行的审议程序和信息披露情况 于 <宁波美诺华药业股份有限公司 ensp="ensp" 年股票期权与限制性股票激励计划="年股票期权与限制 性股票激励计划" 草="草"> 案）及其摘要>的议案》、《关于 <宁波美诺华药业股份有限公司 ensp="ensp" 年股票期权="年股票期 权"> 与限制性股票激励计划实施考核管理办法>的议案》、《关于提请股东大会授权董 事会办理股票期权与限制性股票激励计划有关事项的议案》等议案，关联董事对 相关议案进行了回避表决，公司独立董事发表了同意的独立意见。具体内 ...

根据《反垄断法》第五十九条的规定，反垄断执法机构确定罚款数额应当考虑行为的性质、程度、持续 时间和消除违法后果、配合程度及停止违法行为情形及其他有关情形。天津市市场监督管理委员会综合 上述因素，根据《反垄断法》第五十六条第一款、第五十九条，决定责令公司停止违法行为，并对公司 作出行政处罚如下：(一)没收违法所得17,899,200.00元。(二)并处2023年度销售额8%的罚款 61,627,211.20元，结合宽大情形，减免罚款额的30%，减免后实际罚款43,139,047.84元，以上罚没款合 计61,038,247.84元。 本次罚没金额占公司合并报表范围最近一个会计年度经审计的营业收入和归属于上市公司股东的净利润 的比例分别为2.83%和72.53%。上述罚没款金额将相应减少公司2025年度归属于上市公司股东的净利润 61,038,247.84元。公司本次收到的《行政处罚决定书》不触及《上海证券交易所股票上市规则》等规定 中关于公司重大违法强制退市情形，亦不会对公司生产经营产生持续影响。 智通财经APP讯，联环药业(600513.SH)发布公告，近日，公司收到天津市市场监督管理委员会下发的 《行政处罚 ...

□减少注册资本 证券代码：603707 证券简称：健友股份 公告编号：2025-049 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/4/29，由董事长唐咏群先生提议 回购方案实施期限 2025 年 5 月 20 日~2026 年 5 月 19 日 预计回购金额 2,000万元~4,000万元 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做 出回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 88万股 累计已回购股数占总股本比例 0.05% 累计已回购金额 1,022.07万元 实际回 ...

Core Viewpoint - The legal opinion letter from Beijing Zhonglun (Shanghai) Law Firm confirms that Jiangxi Tianxin Pharmaceutical Co., Ltd.'s differentiated dividend distribution for the year 2024 complies with applicable laws and regulations, ensuring no harm to the interests of the company and its shareholders [10]. Group 1: Differentiated Dividend Distribution - The company plans to distribute a cash dividend of 0.68 RMB per share (including tax) to all shareholders, totaling approximately 295.92 million RMB based on the actual number of shares eligible for profit distribution [6]. - The total amount for cash dividends and share repurchase is approximately 355.92 million RMB, which accounts for 54.65% of the net profit attributable to shareholders for the year [6]. Group 2: Share Repurchase Plan - The company approved a share repurchase plan on January 22, 2024, with a total fund allocation between 60 million RMB and 120 million RMB, at a maximum price of 33.00 RMB per share, to be executed within 12 months [5]. Group 3: Legal Compliance and Verification - The law firm verified that all documents provided by the company are true, accurate, and complete, and that the company has obtained all necessary government approvals and licenses [2][3]. - The law firm emphasizes that it does not provide professional opinions on accounting, auditing, or evaluation matters, relying instead on documents from relevant intermediaries [4].

Group 1 - Yiming Pharmaceutical announced that its stock price had deviated by over 20% in two consecutive trading days, indicating abnormal trading fluctuations. The company is undergoing a potential change in control, but the completion of the share transfer agreement remains uncertain [3] - Yongjin Co. clarified that its main business involves the research, production, and sales of cold-rolled stainless steel strips, and it does not engage in solid-state battery products [4] - Gongchuang Turf reported that domestic sports turf contributes a low proportion to its main business revenue, and the impact of domestic football events on its performance is minimal [5] Group 2 - Jinying Co. stated that its revenue from lithium battery materials was 21.72 million yuan in 2024, accounting for only 1.70% of its main business revenue, and it does not involve solid-state battery business [6] - Beizhi Technology has reached a strategic cooperation intention with Xingdong Jiyuan to collaborate on humanoid robots in smart logistics applications, aiming for mutual benefits and sustainable development [7] - Hengdian Film announced plans to jointly invest with its wholly-owned subsidiary to establish a new cinema development company with a registered capital of 50 million yuan, where Hengdian Film will contribute 45 million yuan [8] Group 3 - Tiankang Biological reported a sales revenue of 345 million yuan from pig sales in May, a year-on-year decrease of 19.95%, with a total of 1.2851 million pigs sold in the first five months of 2025, reflecting a year-on-year growth of 12.49% [11] - Qu Mei Home's director reduced 58,000 shares during the stock's abnormal trading period, while no other executives engaged in stock trading during this time [13] - Tengda Construction won a bid for the Fanglin Automotive Cloud Warehouse project with a contract value of 349 million yuan, representing approximately 9.38% of its projected revenue for 2024 [15]

Market Performance - On June 9, the Shanghai Composite Index rose by 0.43%, the Shenzhen Component Index increased by 0.65%, and the ChiNext Index gained 1.07%[3] - Market turnover reached 1.31 trillion, an increase of approximately 130 billion compared to the previous trading day[1] Sector Analysis - All sectors except food and beverage saw gains, with pharmaceuticals, military industry, agriculture, and textiles leading the increases[1] - The military and innovative pharmaceuticals sectors have shown significant strength, driven by recent geopolitical events and advancements in clinical research[1] Economic Indicators - In May, the Consumer Price Index (CPI) decreased by 0.1% year-on-year, while the Producer Price Index (PPI) fell by 0.4% month-on-month, with a year-on-year decline of 3.3%[5] - For the first five months of the year, China's total goods trade value reached 17.94 trillion, reflecting a year-on-year growth of 2.5%[6] Investment Trends - In the first week of June, new fund issuance exceeded 31 billion, with equity funds showing a "high volume, low amount" characteristic, totaling only 5.82 billion[11] - Public REITs' total market value surpassed 200 billion for the first time, with the Shanghai Stock Exchange accounting for nearly 70% of this total[12][13]

Group 1: Pharmaceutical Sector - The pharmaceutical sector is currently stable and categorized as a secondary hotspot, with an accelerated performance that poses potential risks to previously high-performing thematic stocks [1] - The strength of the pharmaceutical stocks' performance hinges on whether funds can flow into underperforming sub-sectors such as traditional Chinese medicine and biopharmaceuticals, indicating a shift in sector dynamics [1] - Investors are advised to closely follow market hotspots, as capturing these trends typically yields better results than straying from them; they should focus on stocks with advantageous price trends or fundamentals and patiently await opportunities [1] Group 2: Digital Currency Sector - The digital currency sector shows a standard bullish trend, although trading volume has decreased, leading to a fluctuating market condition [1] - If digital currency stocks can reclaim previous highs, it will indicate strength and provide buying opportunities during pullbacks, aiding in the identification of strong stocks [1] Group 3: Nuclear Fusion Sector - The nuclear fusion sector has recently shown strong performance, with some stocks hitting the daily limit, indicating it was previously a primary hotspot worth monitoring [2] - The sector is approaching new highs, facing a choice between a breakout or a pullback; a successful breakout will solidify its strong position, while a pullback that holds key support levels will still indicate strong oscillation [2] - Investors are encouraged to consider which sectors may lead in a unidirectional market, emphasizing the importance of selecting the right sectors and stocks for optimal investment outcomes [2]